GSK focused on split as cost checks, COVID-19 easings aid earnings
Plans for GSK to split in two are “well underway” it said on Wednesday, as a cost clampdown and rising clinic visits for critical treatments after an easing of COVID-19 curbs helped it land better-than-forecast first-quarter earnings. GSK, which trails competitors in the coronavirus vaccines race, is under the microscope after a report that U.S. … Read more